Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | XPO1 | O14980 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31361106 | 0.91 | ALDH1A1 (0.40) | MEN1CYP2C9CYP2C19KMT2AHSD17B10 | |
| SCHEMBL25949117 | 0.90 | ALDH1A1 (0.34) | MEN1CYP2C9CYP2C19KMT2AHSD17B10 | |
| SCHEMBL25316579 | 0.88 | TUBB4A (0.41) | MEN1CYP2C9CYP2C19KMT2AHSD17B10 | |
| SCHEMBL30508760 | 0.88 | TUBB4A (0.41) | MEN1CYP2C9CYP2C19KMT2AHSD17B10 | |
| SCHEMBL25949125 | 0.87 | PDE4B (0.42) | MEN1CYP2C9CYP2C19KMT2AHSD17B10 | |
| SCHEMBL25949110 | 0.87 | LIMK1 (0.32) | LIMK1LIMK2PDE4B | |
| SCHEMBL25946388 | 0.85 | MEN1 (0.39) | MEN1CYP2C9CYP2C19KMT2AHSD17B10 | |
| SCHEMBL25942572 | 0.83 | HSD17B10 (0.50) | MEN1CYP2C9CYP2C19KMT2AHSD17B10 | |
| SCHEMBL25946384 | 0.83 | ALDH1A1 (0.33) | MEN1CYP2C9CYP2C19KMT2AHSD17B10 | |
| SCHEMBL30508770 | 0.82 | MEN1 (0.41) | MEN1CYP2C9CYP2C19KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547663-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | F. Hoffmann-La Roche AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| US-20250115607-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-04-10 | — | — | US | disclosed |
| CN-119451959-A | Imidazo [4,5-C ] pyridine derivatives as SIK modulators for the treatment of rheumatoid arthritis | 豪夫迈·罗氏有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118591534-A | Novel benzimidazole pyridine derivatives | 豪夫迈·罗氏有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024003209-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | H1-3, H1-2, H1-4 | MEN1 1114/4885CYP2C9 120/4885CYP2C19 38/4885 |
| US-20250115607-A1 | PYRIDINE DERIVATIVES | ADORA1, CYP1A1, MT-ND1 | MEN1 609/4885CYP2C9 151/4885CYP2C19 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.